Striving for new therapies that make patients' lives better

We have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials. Our product candidates address many serious medical conditions including cancer, eye diseases, inflammatory diseases, pain, cardiovascular diseases, and allergic conditions.

Peter Powchik, MD Senior Vice President, Clinical Development "We have the enviable ability to add several additional fully human antibodies to the clinical pipeline each year due to the productivity of our discovery and development platforms."

Velocigene® Technology

Regeneron scientists have developed novel methods for assigning functions to genes and creating preclinical disease models.

More On Our Technology Platform

Clinical Trials

Regeneron has investigational product candidates progressing through all stages of human clinical trials.

See if there are clinical trials that might be right for you

Product Candidate

Indication under Study

ARCALYST®(rilonacept) Gout flare prevention in patients initiating uric acid-lowering therapy
EYLEATM (aflibercept) Injection Central retinal vein occlusion, diabetic macular edema
Aflibercept concentrate Previously-treated metastatic colorectal cancer, (1st line) metastatic prostate cancer
Sarilumab (REGN88; IL-6R Antibody) Rheumatoid arthritis
REGN727 (PCSK9 Antibody) LDL cholesterol reduction
REGN475 (NGF Antibody)* Osteoarthritis of the knee, other pain indications
*On Clinical Hold
REGN668 (IL-4R Antibody) Eosinophilic asthma
REGN421 (DII4 Antibody) Advanced malignancies
REGN910 (Ang2 Antibody) Advanced malignancies
REGN668 (IL-4R Antibody) Atopic dermatitis
REGN846 Atopic dematitis
REGN728 Undisclosed

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Close
Form content here please :)